1. Home
  2. LARK vs KROS Comparison

LARK vs KROS Comparison

Compare LARK & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Landmark Bancorp Inc.

LARK

Landmark Bancorp Inc.

HOLD

Current Price

$30.85

Market Cap

185.5M

Sector

Finance

ML Signal

HOLD

Logo Keros Therapeutics Inc.

KROS

Keros Therapeutics Inc.

HOLD

Current Price

$10.61

Market Cap

206.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LARK
KROS
Founded
1885
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
185.5M
206.0M
IPO Year
2001
2020

Fundamental Metrics

Financial Performance
Metric
LARK
KROS
Price
$30.85
$10.61
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$21.86
AVG Volume (30 Days)
16.8K
313.0K
Earning Date
04-29-2026
05-06-2026
Dividend Yield
3.07%
N/A
EPS Growth
35.84
146.00
EPS
0.83
N/A
Revenue
N/A
$243,864,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2,751.79
P/E Ratio
$37.50
N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.57
$9.69
52 Week High
$32.39
$22.55

Technical Indicators

Market Signals
Indicator
LARK
KROS
Relative Strength Index (RSI) 55.39 45.71
Support Level $25.46 $10.14
Resistance Level $30.80 $11.55
Average True Range (ATR) 0.63 0.58
MACD -0.07 -0.08
Stochastic Oscillator 41.45 13.77

Price Performance

Historical Comparison
LARK
KROS

About LARK Landmark Bancorp Inc.

Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and Southwest Kansas.

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Share on Social Networks: